Day 1 - March 25, 2021
Indira Nath (born 14 January 1938) is an Indian immunologist. Her major contribution in medical science deals with mechanisms underlying immune unresponsiveness in man, reactions and nerve damage in leprosy and a search for markers for viability of the Leprosy bacillus. Prof. Nath's fields of specialisations are Immunology, Pathology, Medical biotechnology and communicable diseases. She has also mentored many MBiotech, MD, and PhD students and made contributions to education, ethics, medical and science policies, women scientists' as well as health/bio security issues.
13:05 - 13:50 The German Research Ombudsman: Supporting researchers in cases of conflict - Perspectives from the German Research Ombudsman
Prof. i.R. Dr. Renate Scheibe, German Research Ombudsman, DFG and University of Osnabrück
The German Research Ombudsman (Ombudsman für die Wissenschaft) is a committee that assists all scientists and researchers in Germany in questions of research integrity. In addition, the committee offers confidential and solution-oriented conflict mediation. Next to the national committee, also the so-called local ombudspersons give advice based on the rules of good scientific practice. The talk will give an overview of the possibilities to support researchers in typical conflict situations, focusing on researchers in early career phases.
Renate Scheibe studied pharmacy at the Ludwig Maximilian University in Munich and obtained her license to practice as a pharmacist in 1973. She continued her studies in Munich, and since 1975 in Bayreuth, where she completed her doctorate in 1978. During her time as a scientific assistant at the Department of Plant Physiology at the University of Bayreuth, she also received a NATO Postdoctoral Fellowship to conduct research for one year at the University of Illinois at Chicago. In 1984, she received her habilitation and lecturer’s license for Botany in Bayreuth. Since 1990, she holds the Chair of Plant Physiology at the University of Osnabrück. She retired from active research as a group leader in 2019, and continues to serve with science-related tasks since then.
Renate Scheibe has been a member of the “German Research Ombudsman” Committee appointed by the German Research Foundation (DFG) since 2017, and she will serve for another 4 years as a member of this committee.
Day 2 - March 26, 2021
The classical model of publishing scientific articles after prepublication peer review in paywalled journals is challenged by a number of recent developments. New approaches include open access and open data, preprints, post publication and open review, registered reports, and living documents, among others. Collectively this promises greater accessibility, pace, transparency, robustness and trustworthyness, sharing and reuse of data, as well as completeness of available evidence. In my talk I will review these developments and the challenges and opportunities they bring, discuss how they are driven by the current debate on research waste and non-reproducibility of results, and speculate whether and how all this will change the life sciences.
In preclinical as well as in clinical studies Ulrich Dirnagl’s research has revealed pathobiology which impact on the outcome after a stroke. These include deleterious as well as endogenous protective mechanisms, as interactions of the brain with other systems of the body after it has been injured. Several of these mechanism can be therapeutically targeted, clinical trials are under way. In addition, through meta-research he was able to identify opportunities for improving research practice and to obtain evidence for the impact of interventions targeted to increase the value of biomedical research. At the Charité Universitätsmedizin Berlin Ulrich Dirnagl serves as Director of the Department of Experimental Neurology.
Since 2017 he is also the founding director of the QUEST Center for Transforming Biomedical Research at the Berlin Institute of Health. QUEST aims at overcoming the roadblocks in translational medicine by increasing the value and impact of biomedical research through maximizing the quality, reproducibility, generalizability, and validity of research.